UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 OMB APPROVAL
OMB Number: 3235-0058
Expires: April 30, 2025
Estimated average burden hours per response ... 2.50
 
SEC FILE NUMBER
333-216465
 
CUSIP NUMBER
92851B 102

 

(Check one):    o Form 10-K o  Form 20-F o  Form 11-K x  Form 10-Q o  Form 10-D o  Form N-SAR o  Form N-CSR
     
    For Period Ended: October 31, 2022
     
    o   Transition Report on Form 10-K
     
    o   Transition Report on Form 20-F
     
    o   Transition Report on Form 11-K
     
    o   Transition Report on Form 10-Q
     
    o   Transition Report on Form N-SAR
     
    For the Transition Period Ended:

 

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

 


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

VitaSpring Biomedical Co. Ltd.

Full Name of Registrant

 

Former Name if Applicable

 

400 Spectrum Center Drive, Suite 1620

Address of Principal Executive Office (Street and Number)

 

Irvine CA 92618

City, State and Zip Code

 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

ý (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

  

ý (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

o (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

PART III — NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The registrant was not, without unreasonable effort or expense, able to file its Quarterly Report on Form 10-Q for the quarter ended April 30, 2020 by June 15, 2020. The registrant anticipates that it will file its Form 10-Q within the "grace" period provided by Securities Exchange Act Rule 12b-25. 

 

 

PART IV — OTHER INFORMATION

 

(1)   Name and telephone number of person to contact in regard to this notification
         
Scott C. Kline   (949)   271-6355
(Name)   (Area Code)   (Telephone Number)
             

 

(2)   Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
    Yes ý     No o
     
(3)   Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
    Yes o     No ý
     
   

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 

 

VitaSpring Biomedical Co. Ltd.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

         
Date: December 13, 2022 By: /s/ Kao Cheng-Hsiang
      Name: Kao, Cheng-Hsiang
      Title: Chief Executive Officer

 

 

 

VitaSpring Biomedical (CE) (USOTC:VSBC)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos VitaSpring Biomedical (CE).
VitaSpring Biomedical (CE) (USOTC:VSBC)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos VitaSpring Biomedical (CE).